High expression of RUNX1 is associated with poorer
Recommend Documents
Oct 15, 2011 - protein in head and neck squamous cell carcinoma (HNSCC) patients in association with outcome. Experimental Design: XRCC1 protein ...
Dec 30, 2011 - Peter J Campbell, Martin Griesshammer, Konstanze Dohner, Hartmut Dohner, Rajko Kusec, Hans C idiopathic myelofibrosis is associated with ...
Mar 22, 2013 - Results from other studies in Germany and the Netherlands confirm this association. [8,9]. Only a few authors have addressed health-related.
Jun 8, 2018 - ARC-NET Applied Research on Cancer Centre at Department of Diagnostics and ... University and Hospital Trust of Verona, Verona, Italy.
Mar 5, 2014 - KHOS-CD49f shRNA GFP, KHOS cells were plated at densities ...... 89. SHROOM2. 32. EXT1. 90. SLC25A4. 33. FAT1. 91. SLC4A4. 34. FHL2.
Feb 28, 2013 - same region of interest was used for analysis as in the MATLAB method. The region ..... noma; Pl/R Ova = platinum refractory ovarian cancers;.
self-reported treatment satisfaction and health-related quality of life in patients with type 2 diabetes. ... filtration in skeletal muscle, independently of body mass ...
apy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. ... status as a predictor of t
eDivision of Medicine, Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
May 9, 2018 - Comprehensive Sickle Cell Clinic at the Children's Hospital of. Pittsburgh in ... self-reported medical, psychiatric, neurologic, or pain-related diagnosis and not ..... Hassett AL, Cone JD, Patella SJ, Sigal LH. The role of ...
Tian et al could stimulate cancer cell proliferation, suggesting that. AKR1C3 is a potential therapeutic target for a number of malignancies.9 AKR1C2 could serve ...
Jun 12, 2012 - semiquantitative classes were used to describe the number of stained tumor .... Caspase 8 (#9746), Caspase 9 (#9502), Cyclin B1 (#4138S),. Cyclin D3 ..... Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., Morton DL,. Ross MI ... Ess
Jun 14, 2013 - This work was supported by the Inger and John Fredriksen Foundation for. Ovarian Cancer Research, South-Eastern Norway Regional Health ...
With respect to survival, a higher cytoplasmic expression of p-mTOR was associated with a worse .... These cases were defined as the radio-resistant group.
Cancer Immunology, Immunotherapy. October ... Cancer Immunol Immunother (2013) 62: 1609. ... NGEP Prostate cancer Immunotherapy Immunohistochemistry ...
3 days ago - (Sun et al., 2018) and ovarian carcinoma (Brun et al., 2008; Ozalp et al., ... MMP9 transcription (Ghosh, Basu & Roy, 2012). MMP9 has been ...
Mar 2, 2010 - October 1994 and October 2001 (n ¼ 265; Table 1). Patients were ..... P, Knopf JF, Poulleau S, Cocchi P), Lyon (Berger F, Isaac S) and St. Etienne ... Klebig C, Seitz S, Arnold W, Deutschmann N, Pacyna-Gengelbach M,.
Apr 25, 2014 - younger age were associated with stronger grip strength, and more education ..... the American Federation for Aging Research (AFAR) Young ...
Immunohistochemistry. The 5-mm tissue sections intended for microarray ..... 50, http://dx.doi.org/10.1158/0008-5472.CAN-06-3304. 25. Tao H, Mimura Y, Aoe K, ...
Reduced heart rate recovery following a stress test may be considered an indication of ..... [47] H. D. Critchley, C. J. Mathias, O. Josephs et al., âHuman cingu-.
Feb 28, 2013 - 1 Oncology Biomarker Development, Genentech Inc., South San Francisco, California, United States of America, 2 Research Pathology, ...
USA; 3Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas TX 77030, USA;. 4Department of Oral Pathology, Ninth ...
Aug 27, 2013 - Gregory Oakley [34]. Oral normal mucosa OKF6-tert1 ...... Sci. USA 103:11821â11827. 18. Agarwal, R., I. Jurisica, G. B. Mills, and K. W. Cheng.
Sep 25, 2015 - A'Hern RP, Jamal-Hanjani M, Szasz AM, Johnston SR, Reis-Filho JS, Roylance .... Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN.
High expression of RUNX1 is associated with poorer
High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia Supplementary Materials
Supplementary Table S1: Patients’ characteristics in the validating group of CN-AML according to the RUNX1 expression Variable RUNX1high, n = 81 RUNX1low, n = 81 P Median age. y (range) 59 (7–81) 56 (20–83) 0.82 Median OS. d (range) 223 (3–1176) 416 (1–1176) 0.03 FAB subtype, no M0 2 3 1 M1 30 15 0.014 M2 18 27 0.16 M3 0 0 1 M4 22 20 0.86 M5 8 11 0.63 M6 1 5 0.21 61 20 < 0.001 High ERG, no 48 33 0.028 High BAALC, no 28 53 < 0.001 High LEF1, no 44 37 0.35 High MN1, no 54 27 < 0.001 High WT1, no 56 25 < 0.001 High DNMT3B, no 60 21 < 0.001 High TCF4, no 63 18 < 0.001 High ITPR2, no 58 23 < 0.001 High MAPKBP1, no High ERG, BAALC, LEF1, MN1,WT1, DNMT3B TCF4, ITPR2 and MAPKBP1 expression were defined as an expression level above the median of all samples, respectively.
www.impactjournals.com/oncotarget
1
Oncotarget
Supplementary Table S2: RUNX1-associated gene-expression profile using microarray in the testing group probes